Systems and methods for performing apheresis procedures, including photopheresis, are disclosed. The systems and methods utilize a disposable fluid circuit that can be converted from a double needle configuration to a single needle configuration and from a single needle configuration to a double needle configuration. A controller directs the action of system pumps to clear potentially stagnant blood residing in the fluid circuit, tracks system parameters and status before and after conversion, and verifies that the procedure may proceed in its new configuration.

Systems and methods are provided for separating platelets from blood. Prior to blood separation, a volume of blood to be processed, a volume of platelets to be collected, and/or a time required to complete blood draw from a source during a blood separation procedure is determined. Based on that determination, a procedure setpoint is calculated from the completion of the blood draw. Blood is subsequently drawn from a source into a separator in which the blood is separated into a mononuclear cell-containing fraction and a platelet-containing fraction. At least a portion of the platelet-containing fraction is conveyed from the separator, while the volume of the mononuclear cell-containing fraction in the separator increases. The mononuclear cell-containing fraction is conveyed to the source from the separator at the procedure setpoint. The blood draw and separation are then ended.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Apparatus and methods for concentrating platelet-rich plasma is described herein. One variation may generally comprise a tube having a length and defining a channel within and one or more ports located at a proximal end of the tube and in fluid communication with the channel. A plunger may slidably translatable within the channel while forming a seal against an inner surface of the channel and a float may have a pre-selected density and defining a concave interface surface, wherein the float is slidably contained within the channel such that the concave interface surface is in apposition to the one or more ports.

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

A separation container, an adapter device for centrifuge stations of bench centrifuges, and a production device of a medication comprising platelet-rich plasma are disclosed. Also disclosed are a manual production method of platelet-rich plasma and a manual production method of a medication actuable using the container and the devices.

A separation container, an adapter device for centrifuge stations of bench centrifuges, and a production device of a medication comprising platelet-rich plasma are disclosed. Also disclosed are a manual production method of platelet-rich plasma and a manual production method of a medication actuable using the container and the devices.

A processing device includes a pump system, a valve system, a centrifuge, and a controller. A fluid flow circuit is mounted to the device to execute a procedure in which whole blood is processed into a red blood cell product, a plasma product, and a platelet concentrate product. The blood is first separated into red blood cells, buffy coat, and plasma using the centrifuge, with the red blood cells and plasma being removed from the centrifuge, while the buffy coat remains in the centrifuge. The fluid remaining in the centrifuge is circulated through the centrifuge to form a homogenous mixture. Once the mixture is formed, it is separated in the centrifuge into platelet concentrate and red blood cells. A platelet product is then collected by using whole blood or previously collected red blood cells to push the platelet concentrate from the centrifuge to a collection container.